Xeloda prescribing information |
|
 |
|
We offer 10% discount!
Full prescription information or package insert for Xeloda
Click here to read:
Page1 |
Page2 |
Page3 |
Page4 |
Page5
Tumori. 2009 Nov-Dec;95(6):647-51.
Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM)
Medical Oncology Division, S. Maria Hospital, Terni, Italy. roila.fausto@libero.it
Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.
J BUON. 2009 Oct-Dec;14(4):605-8.
Karacetin D, Yalcin B, Okten B, Ozturk S, Maral O, Incekara O.
Radiation Oncology Clinic, Sisli Etfal Research and Training Hospital, Istanbul, Turkey. didemkaracetin@gmail.com
Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Clin Ther. 2009;31 Pt 2:2273-89.
Tkaczuk KH.
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA. ktkaczuk@umm.edu
Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
Biologics. 2008 Dec;2(4):789-811.
Cheng KL, Bradley T, Budman DR.
Monter Cancer Center, North Shore - LIJ Health Systems, Lake Success, New York, USA.
Novel microtubule-targeting agents - the epothilones.
Gastrointest Cancer Res. 2008 Jul;2(4 Suppl):S47-53.
Benson AB.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Advanced gastric cancer: an update and future directions.
Gastrointest Cancer Res. 2008 May;2(3):145-51.
Cohen DJ, Hochster HS.
Department of Medicine/Clinical, Pharmacology, New York University, Cancer Institute, New York, NY.
Rationale for combining biotherapy in the treatment of advanced colon cancer.
Br J Cancer. 2008 Sep 16;99(6):868-74.
Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfert C, Kurek R, Oates J, Baselga J, Hill A.
Department of Medicine, Royal Marsden Hospital, Surrey, UK.
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
Br J Cancer. 2008 Sep 16;99(6):858-61.
Schønnemann KR, Jensen HA, Yilmaz M, Jensen BY, Larsen O, Pfeiffer P.
Department of Oncology, Odense University Hospital, Odense C 5000, Denmark. katrinesch@gmail.com
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
Clin Breast Cancer. 2008 Dec;8 Suppl 4:S166-70.
Cigler T, Vahdat L.
Weill Cornell Medical School, New York, NY 10021, USA.
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
Anticancer Res. 2008 Nov-Dec;28(6B):4129-35.
Pasetto LM, Friso ML, Pucciarelli S, Basso U, Rugge M, Sinigaglia G, Rossi E, Compostella A, Toppan P, Agostini M, Monfardini S.
Istituto Oncologico Veneto, IRCCS, Oncologia Medica 2, Via Gattamelata 64, 35128 Padova, Italy. laramary@libero.it
Role of neoadjuvant treatment in cT3N0M0 rectal cancer.
Support Cancer Ther. 2007 Sep 1;4(4):211-8.
Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB.
Yale University, New Haven, CT.
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
Ther Clin Risk Manag. 2007 Jun;3(3):421-31.
Comella P.
Department of Medical Oncology, National Tumour Institute Naples, Italy.
A review of the role of capecitabine in the treatment of colorectal cancer.
Oncology. 2007;73(3-4):228-37. Epub 2008 Apr 17.
Hess D, Koberle D, Thurlimann B, Pagani O, Schonenberger A, Mattmann S, Rochlitz C, Rauch D, Schuller JC, Ballabeni P, Ribi K; Swiss Group for Clinical Cancer Research.
Department of Internal Medicine, Division of Oncology-Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland. dagmar.hess@kssg.ch
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Oncology. 2007;73(3-4):221-7. Epub 2008 Apr 17.
Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V.
Department ofInternal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany. stefan.boeck@med.uni-muenchen.de
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Oncology. 2007;73(3-4):169-76. Epub 2008 Apr 16.
Dupuis O, Vie B, Lledo G, Hennequin C, Noirclerc M, Bennamoun M, Jacob JH.
Clinique Victor Hugo, Le Mans, France. o.dupuis@centre-jean-bernard.org
Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study.
Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S16-20.
Lee JJ, Chu E.
Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Br J Cancer. 2005 Mar 14;92(5):820-6.
Delord JP, Pierga JY, Dieras V, Bertheault-Cvitkovic F, Turpin FL, Lokiec F, Lochon I, Chatelut E, Canal P, Guimbaud R, Mery-Mignard D, Cornen X, Mouri Z, Bugat R.
1Institut Claudius Regaud, 20-24, rue du Pont Saint Pierre, Toulouse 31052, France.
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda((R))) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Zhonghua Zhong Liu Za Zhi. 2004 Dec;26(12):746-8.
Qian J, Qin SK, Mei JF, Chen YX, Shao ZJ, He ZM.
Department of Medical Oncology, PLA Oncology Center, 81st Hospital, Nanjing 210002, China.
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer.]
Clin Cancer Res. 2005 Mar 1;11(5):1870-6.
Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA.
Division of Hematology/Oncology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Phase II Evaluation of Docetaxel-Modulated Capecitabine in Previously Treated Patients with Non-Small Cell Lung Cancer.
Xeloda review article...
|
|
Anti-cancer drugs
 Xeloda prescribing information
Buy here
|
|
My Basket
